BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 17 February 2015 at 10.30 a.m. Biotie: BTT1023 receives positive opinion for Orphan Drug Designation from COMP The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has in its February meeting issued a positive opinion recommending orphan drug designation for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic liver disease for which there are currently no effective therapeutic treatments. BTT1023 is a fully human monoclonal antibody targeting Vascular Adhesion Protein -1 (VAP-1) and is currently advancing into Phase 2 clinical development. The BUTEO study will be an open label, single arm, multi-centre investigator- sponsored study that will be conducted in partnership with the University of Birmingham, UK and supported through external grant funding. The study is expected to enroll 41 patients and will examine the efficacy, safety and pharmacokinetic properties of BTT1023 in PSC patients. The duration of drug treatment in the study is 11 weeks and the primary efficacy endpoint is reduction of elevated levels of alkaline phosphatase, a blood biomarker of bile duct inflammation. The BUTEO study will be conducted in the UK and is expected to start recruiting patients in Q1/2015. Turku, 17 February 2015 Biotie Therapies Corp. Timo Veromaa President and CEO Further information: For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main media www.biotie.com ABOUT BTT1023 BTT1023 is a fully human monoclonal antibody that specifically binds to vascular adhesion protein-1 (VAP-1). BTT1023 has demonstrated encouraging efficacy and safety in early clinical studies in rheumatoid arthritis and psoriasis patients and in a range of preclinical models of inflammatory diseases, including COPD. More recently, an important role for VAP-1 has also been demonstrated in fibrotic diseases. BTT1023 is transitioning into Phase 2 clinical development in primary sclerosing cholangitis (PSC), a chronic and progressive fibrotic liver disease for which there are currently no effective therapeutic treatments. BTT1023 has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), recommending Orphan Drug Designation for BTT1023 for the treatment of PSC. ABOUT BIOTIE Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and three additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, cocaine dependence, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. [HUG#1894989]
Biotie: BTT1023 receives positive opinion for Orphan Drug
Top 10 Most Recent News Articles
XCMG Climbs Fortune China 500: Strengthens Global Edge
XCMG's Ascent on the Fortune China 500 When it comes to scaling new heights, XCMG Machinery is clearly in the driver's seat, roaring up the Fortune China 500 to claim the 202nd spot, leaping ten ranks from last year. While others may coast, XCMG's trajectory is anything but idle, retaining its crown among Chinese construction machinery titans. The recent summit in Chengdu...
Continue Reading
Seeking Balance in Home Care Staffing: BVNA's Stand
Time to Set the Record Straight: Why Home Care Deserves Our Attention Out here in Pittsfield, Massachusetts, there's a showdown brewing between the Berkshire Visiting Nurse Association (BVNA) and its dedicated crew—those frontline warriors delivering care where it's most personal, right at home. Picture this: a petition lands squarely on the management's desk at 4 p.m....
Continue Reading
New Ambulatory Surgery Center in Alabama Breaks Ground
Breaking New Ground: USOP and SOS Lead the Charge You can almost hear the construction noise starting up in Montgomery, Alabama, where U.S. Orthopaedic Partners (USOP) and Southern Orthopaedic Surgeons (SOS) have just launched an ambitious new project. They're not just cutting ceremonial ribbons; they're slicing into the future of orthopedic care in Central Alabama. The...
Continue Reading
TELUS Digital Named a Key Player in T&S Services 2026
Climbing the Ranks It’s not often you see a tech outfit surge ahead and pull off the kind of leaps TELUS Digital just managed. According to the Everest Group’s 2026 Trust and Safety Services PEAK Matrix® Assessment, TELUS Digital emerged as a Leader for the first time, riding high on advanced AI initiatives. Not just a pat on the back—that’s a big deal...
Continue Reading
DFW Cash Offers: Better Way Home Solutions' Edge
Cash Offers in the Real Estate Maze In Dallas–Fort Worth, selling a home isn't your TV show montage. It's a challenging minefield of tenant headaches, quick moves, and foreclosure pressures. You know, sometimes it's not even about staging photos and waiting for that glamorous open house. Nope, some folks just need cash—and fast. Why Cash is King in DFW Let's cut the...
Continue Reading
Common Thread Advisors: Transforming Change in Business
Navigating the Storm of Change: A New Player in Town You know, just when you think you've got the business world figured out, something sharp comes along. Today, it’s Common Thread Advisors, making its grand entrance to help organizations steer through the dense fog of change. This isn’t your everyday, run-of-the-mill consultancy. No sir, they’re out here with a...
Continue Reading
Blue Moon Metals Gears Up for Springer Mine Revamp
Getting Set for a Big Move Blue Moon Metals Inc. isn't sitting around with its thumbs in its pockets. The company has made some strides with their Springer Tungsten Mine project in Imlay, Nevada. Let's break down what these folks are up to. Refurbished Up for the Fast Track The rock mover here is the refurbishment of the Springer processing plant. You don't just snap your...
Continue Reading
Meta's Bold Move: $25B Offering and New Stocks
Meta's New Financial Adventure Well, when Meta talks money, you better believe the market listens. This time, they’ve got a whopping pair of offerings on the table—one for depositary shares and another for their Class A common stock. Meta, under the ticker NASDAQ:META, isn't holding back, with a $25 billion upsized offering that's bound to rattle some cages. A Deeper...
Continue Reading
Capacity LLC: Finalist in 2026 BeautyMatter Awards
A Nod to Logistics and Beauty When beauty meets logistics, you end up with something like Capacity LLC making headlines in the 2026 BeautyMatter Awards. Now, I ain't one to usually get excited about anything involving freight and boxes, but this isn't just any nod in the 'Best Logistics Solution' category; it speaks volumes about where the beauty business is heading. Why...
Continue Reading
Commvault's Q2 Fiscal 2027 Shines Bright Amid Complexity
Finding Stability in a Shifting Tech Landscape It doesn’t take a crystal ball to see that Commvault is navigating the whirlwind of tech innovation with some serious flair. Their latest quarterly earnings report for Q2 fiscal 2027 is a testament to the rising demand they're experiencing in a world where data protection and resilience are more than just buzzwords. Diving...
Continue ReadingTop 5 Most Recently Viewed Articles
Understanding WisdomTree Funds: A Comprehensive Overview
Exploring WisdomTree Funds Investing in mutual funds and exchange-traded funds (ETFs) has gained tremendous popularity over the past few years, particularly with the rise of digital trading platforms. One prominent player in this arena is WisdomTree, known for its innovative investment strategies across various market sectors. In this article, we will explore the...
Continue Reading
Bioventus Inc. to Announce Q4 2024 Financial Results Soon
Bioventus Inc. Financial Results Announcement Bioventus Inc. (NASDAQ: BVS), a prominent player in the medical technology field, is set to announce its financial results for the fourth quarter of fiscal year 2024. This eagerly anticipated report will be released before market opening on Tuesday, March 11, 2025. Investors and stakeholders are especially keen to hear how the...
Continue Reading
Upcoming insights from reAlpha at a Major Investment Gathering
Exciting Presentation by reAlpha Tech Corp. at a Key Investment Conference Today, reAlpha Tech Corp. (Nasdaq: AIRE) expressed its enthusiasm for participating in the prestigious H.C. Wainwright 27th Annual Global Investment Conference. This event, scheduled from September 8–10, 2025, will take place at the Lotte New York Palace Hotel, a notable venue adding to the...
Continue Reading
Revolutionizing Airline Retail with IBS Software and AWS Partnership
Transforming Airline Retailing with cutting-edge Technology IBS Software has officially announced a groundbreaking partnership with Amazon Web Services (AWS) to enhance airline retailing, and this shift is poised to revolutionize the industry. This strategic collaboration is designed to fuse IBS Software's profound expertise in travel technology with AWS's exceptional...
Continue Reading
Opendoor's Stock Volatility in Focus: What Investors Should Know
Understanding Opendoor's Recent Stock Activity Shares of Opendoor Technologies Inc. (NASDAQ: OPEN) have experienced notable fluctuations in recent weeks. Hedge fund manager Eric Jackson has taken a prominent role in this situation, encouraging investors to remain calm amidst the volatility. Jackson’s Optimistic Take on Stock Projections In a recent post on social media,...
Continue Reading